Literature DB >> 9301997

Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance.

J Versalovic1, M S Osato, K Spakovsky, M P Dore, R Reddy, G G Stone, D Shortridge, R K Flamm, S K Tanaka, D Y Graham.   

Abstract

Fifty-four of 59 (91.5%) clarithromycin-resistant isolates of Helicobacter pylori from different patients possessed either the A2143G (formerly A2058G) or the A2144G (formerly A2059G) mutation in the gene encoding 23S rRNA. The A2143G mutation was significantly more likely to occur in isolates with MICs exceeding 64 mg/L (65% versus 30% with the A2144G mutation; P = 0.01). The majority (26 of 31; 83.9%) of isolates with the A2143G mutation had MICs exceeding 64 mg/L. Peptic ulcer disease recurred in a substantial proportion of patients infected with H. pylori strains containing either the A2143G or the A2144G mutation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301997     DOI: 10.1093/jac/40.2.283

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  63 in total

Review 1.  Macrolide resistance conferred by base substitutions in 23S rRNA.

Authors:  B Vester; S Douthwaite
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

2.  PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates.

Authors:  T Alarcón; D Domingo; N Prieto; M López-Brea
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Clarithromycin resistance in Helicobacter pylori and its clinical relevance.

Authors:  Hua-Xiang Xia; Xue-Gong Fan; Nicholas J Talley
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

4.  PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin.

Authors:  Armelle Ménard; Adriana Santos; Francis Mégraud; Mónica Oleastro
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

5.  In vitro activities of a new ketolide, ABT-773, alone and in combination with amoxicillin, metronidazole, or tetracycline against Helicobacter pylori.

Authors:  S L Pendland; J L Prause; M M Neuhauser; N Boyea; J M Hackleman; L H Danziger
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  T2182C mutation in 23S rRNA is associated with clarithromycin resistance in Helicobacter pylori isolates obtained in Bangladesh.

Authors:  Rasel Khan; Shamsun Nahar; Jinath Sultana; Mian Mashhud Ahmad; Motiur Rahman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City.

Authors:  Gerardo Zerbetto De Palma; Nicolas Mendiondo; Andrés Wonaga; Luis Viola; Daniela Ibarra; Esteban Campitelli; Nicolas Salim; Rodolfo Corti; Cinthia Goldman; Mariana Catalano
Journal:  Microb Drug Resist       Date:  2016-07-08       Impact factor: 3.431

8.  Establishment of a nested-ASP-PCR method to determine the clarithromycin resistance of Helicobacter pylori.

Authors:  Xiao-Feng Luo; Jian-Hua Jiao; Wen-Yue Zhang; Han-Ming Pu; Bao-Jin Qu; Bing-Ya Yang; Min Hou; Min-Jun Ji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

9.  Phenotypic and genotypic analysis of clarithromycin-resistant Helicobacter pylori from Bogotá D.C., Colombia.

Authors:  Alba A Trespalacios; William Otero; Jorge E Caminos; Marcela M Mercado; Jenny Avila; Liliana E Rosero; Azucena Arévalo; Raúl A Poutou-Piñales; David Y Graham
Journal:  J Microbiol       Date:  2013-08-30       Impact factor: 3.422

Review 10.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.